Felippe Coaglio - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Felippe Coaglio's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Felippe Coaglio
Verified
Correspondent, G1
New York
Beats
Killings By Police , Detroit Bankruptcy , Foreclosure And Eviction Crisis , Mass Incarceration , Wrongful Convictions , U.S. Wars , Third World Countries
Stuff I don't know about or care about
Content
Company Info
G1
G1 Therapeutics, Inc. is a biopharmaceutical company based in Research Triangle Park, North Carolina. Founded in 2008, it focuses on developing small molecule therapies for cancer treatment. The company aims to improve patient outcomes by targeting cellular pathways involved in cancer progression. G1 Therapeutics became a subsidiary of Pharmacosmos A/S in September 2024. The company's flagship product, COSELA (trilaciclib), is an FDA-approved drug that protects bone marrow from chemotherapy damage. It is administered intravenously before chemotherapy to enhance patient safety. G1 Therapeutics also has a pipeline that includes lerociclib, a CDK4/6 inhibitor, and other investigational compounds aimed at cancer treatment. The company collaborates with organizations like GeneCentric Therapeutics and AstraZeneca to advance its research and clinical trials.
, ,
'+1 919-213-9835
Founded: 2008